牛牛AI助理已提取核心訊息
On February 15, 2024, Samarth Kulkarni, CEO of CRISPR Therapeutics, executed a sale of company stock. The transaction involved the disposal of 20,000 common shares at prices ranging from $79.9359 to $81.6645 per share, resulting in a total market value of $1,607,177.46. Prior to the sale, Kulkarni acquired the same number of shares through the exercise of derivative securities at a price of $19.12 per share. Following the transactions, Kulkarni's direct holdings in CRISPR Therapeutics amounted to 187,377 shares. Additionally, Kulkarni has an indirect beneficial ownership of 200,000 shares through The Kulkarni 2023 GRAT, an entity not directly tied to the reported transactions.
On February 15, 2024, Samarth Kulkarni, CEO of CRISPR Therapeutics, executed a sale of company stock. The transaction involved the disposal of 20,000 common shares at prices ranging from $79.9359 to $81.6645 per share, resulting in a total market value of $1,607,177.46. Prior to the sale, Kulkarni acquired the same number of shares through the exercise of derivative securities at a price of $19.12 per share. Following the transactions, Kulkarni's direct holdings in CRISPR Therapeutics amounted to 187,377 shares. Additionally, Kulkarni has an indirect beneficial ownership of 200,000 shares through The Kulkarni 2023 GRAT, an entity not directly tied to the reported transactions.
2024年2月15日，CRISPR Therapeutics首席執行官薩瑪斯·庫爾卡尼執行了公司股票的出售。該交易涉及以每股79.9359美元至81.6645美元的價格出售20,000股普通股，總市值爲1,607,177.46美元。出售之前，庫爾卡尼通過行使衍生證券以每股19.12美元的價格收購了相同數量的股票。交易完成後，庫爾卡尼在CRISPR Therapeutics的直接持股量爲187,377股。此外，庫爾卡尼通過庫爾卡尼2023年GRAT擁有20萬股股票的間接實益所有權，該實體與報告的交易沒有直接關係。
2024年2月15日，CRISPR Therapeutics首席執行官薩瑪斯·庫爾卡尼執行了公司股票的出售。該交易涉及以每股79.9359美元至81.6645美元的價格出售20,000股普通股，總市值爲1,607,177.46美元。出售之前，庫爾卡尼通過行使衍生證券以每股19.12美元的價格收購了相同數量的股票。交易完成後，庫爾卡尼在CRISPR Therapeutics的直接持股量爲187,377股。此外，庫爾卡尼通過庫爾卡尼2023年GRAT擁有20萬股股票的間接實益所有權，該實體與報告的交易沒有直接關係。
有用
沒用